Regulatory Disclosure Details

Facility Details

  • Location: Bhayla, Ahmedabad
  • Facility Type: EU-GMP approved Women's Hormone manufacturing facility
  • Size: 1.0 lakh square feet
  • Production Status: Commercial production successfully commenced
  • Inauguration: Conducted by Chairman Dr. K. L. Mehta alongside long-serving women employees of the organization

Manufacturing Capacity

  • Annual Tablet/Capsule Capacity: 194 million units
  • Annual Ointment/Gel Capacity: 1.5 million units
  • Capacity Increase: In-house hormone manufacturing capacity increased by nearly 20%

Technical Specifications

  • Dosage Forms Supported: Tablets, soft gel capsules, ointments, and gels
  • Regulatory Standards: EU-GMP approved
  • Manufacturing Systems: Fully integrated closed-loop manufacturing systems
  • Compliance: 21 CFR-compliant equipment and Quality by Design (QbD) principles
  • Technology: Advanced gelatin processing systems with precision-controlled agitation and jacketed vessels
  • Monitoring: Real-time online process monitoring for batch-to-batch reproducibility

Strategic Context

The facility addresses growing global attention towards women's healthcare, driven by increased awareness and diagnosis of hormonal disorders, demand for fertility care, and focus on menopause management and hormone replacement therapies. Hormonal medicines require specialized manufacturing due to high potency, sensitive formulations, and stringent contamination control requirements.

Leadership Commentary

Mr. Nirav K. Mehta, Founder, Managing Director & CEO, stated: "Women's healthcare continues to be one of the fastest evolving areas of modern medicine. At CORONA, we believe scientific innovation must be complemented by world-class manufacturing capabilities. This dedicated hormone facility represents our commitment to delivering globally benchmarked quality, strengthening India's pharmaceutical manufacturing ecosystem and ensuring women have access to safe, reliable and high-quality hormone therapies."

Company Background

CORONA Remedies Limited (CIN: L24231GJ2004PLC044656), founded in 2004, is among India's fastest growing pharmaceutical companies in the Top 30 pharmaceutical corporates. The company operates WHO GMP/EU GMP-certified manufacturing facilities and maintains DSIR-approved R&D centres across therapeutic areas including women's healthcare, cardio-diabetes, pain management, and urology.

Investor Relations Contact

  • Company Representative: Ms. Chetna Dharajiya, Company Secretary & Compliance Officer
  • IR Advisors: Strategic Growth Advisors Pvt Ltd. (CIN: U74140MH2010PTC204285)
  • IR Contacts: Mr. Sagar Shroff (+91 98205 19303) and Mr. Tanay Shah (+91 98333 91899)
  • IR Email: sagar.shroff@sgapl.net / tanay.shah@sgapl.net

Additional Information

The intimation is available on the company website at www.coronaremedies.com. The disclosure includes a safe harbor statement noting that forward-looking statements involve known and unknown risks and uncertainties that could cause actual results to differ materially from expectations.